Lynelle Hoch
About Lynelle Hoch
Lynelle Hoch is the President of the Cell Therapy Organization at Bristol Myers Squibb, with over 25 years of experience in various roles within the company.
Current Role: President, Cell Therapy Organization at Bristol Myers Squibb
Lynelle Hoch currently serves as the President of the Cell Therapy Organization at Bristol Myers Squibb. In this role, she leads initiatives aimed at advancing patient health through cell therapy. She guides a team of industry pioneers to propel forward therapeutic innovations, particularly focusing on increasing the speed and reliability of autologous CAR T cell therapy. Her leadership underscores a commitment to advancing cell therapy in treating not just blood cancers, but also autoimmune disorders and neuroinflammatory conditions.
Previous Roles at Bristol Myers Squibb
Lynelle Hoch has held numerous roles at Bristol Myers Squibb over an extensive period. Prior to her current position, she was Senior Vice President, Cell Therapy Franchise Lead, from 2021 to 2023 in Princeton, New Jersey. She also served as General Manager for the United Kingdom and Ireland from 2019 to 2021 in London. Additionally, she was Vice President of Immuno-Oncology Marketing from 2016 to 2019, and Vice President of Oncology Sales from 2012 to 2016. Her earlier roles at the company included positions in marketing, sales, and strategy across different therapeutic areas.
Experience and Contributions in Cell Therapy
In her role as President of the Cell Therapy Organization, Lynelle Hoch focuses on several key areas including exploring new targets and dual targeting approaches to enhance CAR T cell therapies' efficacy. She plays a pivotal role in expanding CAR T cell therapy applications beyond oncology to address autoimmune and neuroinflammatory conditions. Hoch emphasizes the importance of collaboration with global regulatory bodies to navigate and highlight the complexities and value of cell therapy. Innovation and partnerships are central to her approach in advancing this cutting-edge field.
Educational Background
Lynelle Hoch holds a Bachelor of Science (B.S.) in Civil Engineering with a minor in Environmental Science from Penn State University. Her educational foundation in engineering and environmental science provides a multidisciplinary approach to her work in the pharmaceutical and biotechnology sectors. This background supports her ability to address complex scientific challenges and contribute to innovative therapeutic advancements, particularly in the field of cell therapy.
Industry Involvement and Thought Leadership
Lynelle Hoch is actively involved in mentoring and championing others within the industry. She has authored an article on the future of cell therapy for cancer treatment, emphasizing the potential applications beyond blood cancers. Her discussions include exploring treatments for autoimmune disorders, neuroscience, and solid tumors. Hoch also highlights the importance of collaboration and regulatory engagement to ensure the successful development and application of cell therapy. Her thought leadership in the industry underscores her commitment to driving forward vital advancements in patient care.